Background: The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system. Methods: Data for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characterist...
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To iden...
PURPOSE: Germline mutations in the BRCA1 and BRCA2 genes confer increased susceptibility to ovarian ...
Abstract Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent...
Background: The distribution of ovarian tumour characteristics differs between germline BRCA1 and BR...
Background: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
Background: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
BACKGROUND: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To iden...
PURPOSE: Germline mutations in the BRCA1 and BRCA2 genes confer increased susceptibility to ovarian ...
Abstract Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent...
Background: The distribution of ovarian tumour characteristics differs between germline BRCA1 and BR...
Background: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
Background: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
BACKGROUND: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a t...
BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
Population-based genome wide association studies have identified a locus at 9p22.2 associated with o...
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To iden...
PURPOSE: Germline mutations in the BRCA1 and BRCA2 genes confer increased susceptibility to ovarian ...
Abstract Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent...